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Abstract
Atopic asthma is a chronic inflammatory pulmonary disease characterised by recurrent episodes of wheezy,
laboured breathing with an underlying Th2 cell-mediated inflammatory response in the airways. It is currently
treated and, more or less, controlled depending on severity, with bronchodilators e.g. long-acting beta agonists
and long-acting muscarinic antagonists or anti-inflammatory drugs such as corticosteroids (inhaled or oral),
leukotriene modifiers, theophyline and anti-IgE therapy. Unfortunately, none of these treatments are curative and
some asthmatic patients do not respond to intense anti-inflammatory therapies. Additionally, the use of long-term
oral steroids has many undesired side effects. For this reason, novel and more effective drugs are needed. In this
review, we focus on the CD4+ Th2 cells and their products as targets for the development of new drugs to add to
the current armamentarium as adjuncts or as potential stand-alone treatments for allergic asthma. We argue that in
early disease, the reduction or elimination of allergen-specific Th2 cells will reduce the consequences of repeated
allergic inflammatory responses such as lung remodelling without causing generalised immunosuppression.
Introduction
Asthma is a serious chronic inflammatory lung disease
characterised by recurrent episodes of wheezy laboured
breathing with prolonged expiration accompanied by
dry coughing and viscous mucus. These symptoms
result from bronchoconstriction, bronchial mucosal
thickening by oedema, eosinophilic infiltration, bron-
chial wall remodelling and excessive mucus production
with plugging of the conducting airways in the lungs.
These airway changes lead to increased bronchial hyper-
reactivity to a variety of allergic and non-allergic stimuli.
Obstruction is usually reversible, either spontaneously
or in response to appropriate therapy. Asthma affects
approximately 300 million people worldwide and can be
fatal. Atopic or allergic asthma generally occurs in child-
hood or young adulthood (under the age of 40) in about
70-80% of cases and is caused by common allergens e.g.
pollens, house dust, animal dander, inhalants, foods,
drugs and occupationally encountered dust. Atopic
asthma is characterised by detectable allergen-specific
IgE and a positive skin test upon allergen provocation.
The most severe chronic refractory asthma accounts for
5-10% of adults with asthma and is characterised by per-
sistent symptoms and frequent exacerbations, despite
treatment with high dose inhaled and/or oral corticos-
teroids and inhaled b2 adrenoceptor agonists. These
patients are at greater risk of fatal and near-fatal exacer-
bations and display serious unremitting symptoms,
resulting in a considerable impact on quality of life, dis-
proportionate use of health care resources and adverse
effects from regular systemic steroid use.
The allergic immune response is a complex process
beginning with the activation of allergen-specific Th2
cells by antigen presenting cells (APCs) followed by
their proliferation, cytokine production, helper functions
and the emergence of memory cells (Figure 1). The
resulting pathophysiological response includes lung eosi-
nophilic inflammation, oedema, smooth muscle contrac-
tion and increased mucus production, resulting in
airway obstruction and eventual lung damage. Numer-
ous experimental models and clinical studies support a
central role of allergen-specific Th2 cells in pathophy-
siological responses [1-4]. Although much is known
about the pathogenesis of the disease, the mechanisms
underlying Th2 cell differentiation and perpetuation
remain unclear. Allergen-specific memory Th2 cells take
up long-term residence within experimental mice after
recovering from a single episode allergic asthma [5]
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gen-specific IgG1 and persistent inflammatory chronic
lung infiltrates. Asthma exacerbations are induced by
respiratory tract allergen challenge leading to pathology
resembling patients [6-8]. A reduction or elimination of
specific Th2 responses permits the treatment of disease
without causing generalised immunosuppression and
makes it a prime target for disease abrogation. Although
current asthma therapies (especially inhaled corticoster-
oids and b2-agonists) efficiently control the disease,
development of novel drugs is crucial for disease control
in patients with severe, corticosteroid-insensitive asthma,
as well as for improvement of existing therapies in
terms of a more favourable side effect profile [9]. Addi-
tionally, the use of highly active drugs that reduce dis-
ease in the early stages may obviate the need for high
dose steroids later on and may reduce the potential for
unremitting, steroid-resistant disease. Current asthma
therapies do not cure the disease and symptoms return
soon after treatment is terminated. Treatment in the
late stages of chronic, severe, unremitting allergic
asthma may be too late. It is therefore, important to
start treatment early to reduce disease. In the early
stages of disease, allergen-specific Th2 memory cells
appear to play an important role in initiating the
immune response against the offending allergen. Elimi-
nating these pathogenic cells at an early stage may lead
to complete disease remission. There is a myriad of stra-
tegies to eliminate Th2 memory cells that are promising.
This review focuses on these targets during the evolu-
tion of the Th2-mediated allergic immune response
from allergen presentation to activation and survival of
Th2 memory cells (Figure 1).
Improvement of existing anti-Th2 cell therapies
Inhaled and oral corticosteroids, leukotriene modifiers,
theophyline, anti-IgE and specific allergen immunother-
apy (AI) are well-established treatments for asthma [10].
Of these therapies, only AI specifically targets Th2 cells
[11]. AI is thought to function by either skewing the
allergic Th2 response towards Th1 immunity or gener-
ating regulatory T cells (Tregs) [12,13]. While the
mechanism remains controversial, AI is effective in a
subset of patients. Classical immunotherapy or “allergy
shots” in the last years is evolving towards non-inject-
able forms like subcutaneous and sublingual immu-
notherapy [13,14]. Progress in AI focuses on the dose
and nature of the allergens, with higher allergen doses
improving AI effectiveness [15] and chemically modified
allergens (allergoids) increasing efficacy [14,16]. The
production of recombinant allergens of common aller-
gens from DNA sequences that can be mutated, frag-
mented or chimerised leads to efficient hypoallergenic
mixtures of allergens for treatment [14,17,18]. Addition-
ally important is the ability of producing T cell epitopes
without B cell epitopes, which reduces adverse reactions
[12,16,17] or new technologies like covalently linked T
cell epitopes [14], DNA vaccines encoding allergens
[19], production of fusion proteins to increase allergen
presentation [20], or expression of recombinant aller-
gens in lactic bacteria able to colonise the gut [21].
Equally promising is the production of random peptide
libraries to determine structural equivalents, so called
mimotopes [14], producing shorter peptides [16,22],
though patients may develop de novo IgE antibodies
Figure 1 Helper Th2 cells play a central role in allergic asthma
and could be targeted through individual allergic immune
processes.( 1) Allergen handling and presentation by activated APC
to naïve CD4+ T cells induces their activation. (2) Activated naïve
CD4+ T cells differentiate to Th2 cells, or (3) possibly to other types
of helper T cells e.g. Th1, Th17 or Treg cells. (4) Secondary exposure
to allergen leads to Th2 cell activation, (5) as well as their migration
into the lungs. (6) Activated Th2 cell-mediated asthma is caused in
part by the secretion of interleukins e.g. IL-4, IL-5 and IL-13. These
cytokines stimulate B cell activation and IgE secretion. Th2 cell
cytokines and IgE activate cells of the innate immune system e.g.
eosinophils, mast cells, etc. causing the release of vasoactive, pro-
inflammatory mediators, smooth muscle contraction, mucus
hypersecretion, oedema and, eventually, airway remodelling. (7)
Homeostasis and survival of memory T cells in the lymph nodes
and lungs perpetuates disease. Interruption of these molecular and
cellular targets may reduce symptoms and pathological
consequences of allergic asthma.
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adjuvants such as monophosphoryl lipid A from Salmo-
nella minnesota [12,23] or heat killed or live Mycobac-
terium tuberculosis did not meet expectations in clinical
trials [14], other adjuvants like fusion proteins with bac-
terial surface layer components [14] and cytosine-gua-
nine dinucleotides (CpG) oligonucleotides (CpG-ODNs)
[9,12,23], as well as routes of allergen delivery, in oral
microencapsulated forms [24] or embedded in nanopar-
ticles [23], are being explored.
Strategies to modulate antigen presentation and Th2 cell
activation
Dendritic cells (DCs) expressing CD11c
+CD11b
+ [25],
CD16
+ [26], CD141
+ [27] or CD8a [28] predispose to
allergic asthma. Sputum and bronchial biopsies of asth-
matic patients contain higher DC numbers in compari-
son to healthy individuals [29,30] and are increased after
allergen exposure [31]. Asthmatic DCs differ in cytokine,
prostaglandin (PG), and chemokine synthesis and costi-
mulatory molecule expression compared to healthy con-
trols [32-34]. In addition, allergen-pulsed DCs from
asthmatic patients, but not healthy controls, preferen-
tially stimulate T- cells to produce IL-4 [35]. DCs from
asthmatics produce high amounts of PGE2 [34], which
decreases IL-12 [36] and increases CCL17 and CCL22
production [37] from DCs causing the polarisation of
DCs, which promote Th2 cell differentiation and
recruitment. Recently, thymic stromal lymphopoietin
(TSLP) has emerged as a key mediator, which promotes
DC-induced Th2 differentiation through the interaction
of OX40:OX40L [38,39]. Inhibition of DC-mediated
antigen presentation represents a suitable treatment
option for allergic diseases. While DCs are the most
potent APCs, other cells also contribute to antigen pre-
sentation and may provide useful targets. Table 1 illus-
trates the cell type, target and mechanism of action for
compounds and biologicals that reduce antigen presen-
tation to Th2 cells and their subsequent activation.
Interference with Th2 differentiation and activation
Antigen presentation induces clonal expansion and dif-
ferentiation of naïve Th cells into mature Th1, Th2,
Th17 or inducible Tregs [reviewed in [40]]. Th2 cell
polarisation is mediated by transcription factors, includ-
ing GATA-3, which are crucial for Th2 lineage commit-
ment. Initial signals that drive Th2 differentiation
induce expression of the GATA-3 [41], which mediates
Th2 differentiation by inducing chromatin remodelling
of Th2 gene loci, direct transactivation of Th2 gene
expression and inhibition of IFNg expression [42].
Furthermore, GATA-3 expression must be sustained to
maintain a Th2 phenotype [42,43]. Beside other impor-
tant factors, microRNAs have recently emerged as
regulators of gene expression during differentiation and
function [reviewed in [44,45]]. Numerous microRNAs
play important roles in asthma [46] and selective inhibi-
tion of these molecules can be utilised to specifically tar-
get development of Th2 cells. Examples of other signal
transduction pathway targets and their inhibitors are
listed in Tables 2 and 3. Unfortunately, most of these
targets are not selectively expressed in Th2 cells and
their inhibitors have broad immunosuppressive effects.
Modulation of effector cytokines
The interplay between cells and cytokines involved in
Th2-mediated disease is complex. Th2 cells secrete and
express a variety of cytokines and receptors [40]. In the
past decade, mAbs targeting the most prominent Th2
cytokines, IL-4, IL-5 and IL-13 have had variable success
in clinical trials and the perception is that effectiveness
will be improved by inhibiting two or all of them simul-
taneously. Furthermore, additional cytokines including
IL-9 and IL-31 are secreted by Th2 cells and might
represent novel or additive targets. Moreover, cytokines
secreted by other cells such as Th1, Th17 and Tregs
may suppress Th2 cell function. Importantly, augment-
ing suppressive effects and inhibiting disease-promoting
effects of T cells may lead to new compounds. Table 4
illustrates examples of cytokines secreted by Th2 cells,
have direct effects on Th2 differentiation or are involved
in differentiation of other helper T cell subtypes that
could inhibit Th2 cells.
Interference of Th2 cell homing and adhesion
Chemokine-chemokine receptors (CKRs) are a complex
system of 42 molecules and 19 receptors that orches-
trate leukocyte migration in physiologic and pathologic
c o n d i t i o n s[ 4 7 ] .A m o n gC K R s ,C C R 4 ,C C R 8 ,C X C R 4
and CCR3 appear to be selectively expressed on Th2
lymphocytes [48,49] making them potentially important
specific Th2 cell targets. CCR4 regulates chemotaxis of
Th2 cells and its ligands CCL17 and CCL22 are elevated
in allergic asthma [50,51]. Hence, selective CCR4
antagonists, such as bipiperidinyl carboxylic acid amides,
or antibodies directed against CCR4 ligands could be
promising treatments [9,50,51]. However, CCR4 is also
expressed on Tregs and cells with either Th1 or Th2
potential [52] leading to CCR4 inhibitors causing immu-
nosuppressive effects. CCR8 expression also appears to
be increased in lung and airway Th2 cells in asthmatic
patients [53]. Airway eosinophilia and airway hyperre-
sponsiveness (AHR), however, are not diminished in
CCR8
-/- mice [54] and adoptively transferred Th2 cells
not expressing CCR8 accumulate in the lungs [55].
Despite these contrasting results, several CCR8 agonists
[56] and antagonists [57] are in development and might
help to clarify the role of CCR8 in disease pathogenesis.
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lungs [58] and treatment of allergic mice with selective
CXCR4 inhibitors significantly reduces AHR and inflam-
matory responses [59,60], supporting the further devel-
opment of CXCR4 antagonists for asthma treatment.
CCR3, which regulates eosinophil and mast cell accu-
mulation into the lungs [61], is expressed on Th2 lym-
phocytes [62]. CCR3 inhibition is a promising Th2 cell
target that reduces innate and adaptive allergic inflam-
mation [63]. TPI ASM8 is a compound that contains
modified antisense oligonucleotides targeting CCR3 and
the common beta chain of the receptors of GM-CSF,
IL-5 and IL-13, decreases airway inflammation in
humans after allergen exposure and is under clinical
evaluation [64]. Other CKRs that appear to regulate
CD4+ T cell homing to the lungs in asthma include
CCR5, CCR6, CCR7 and CXCR3 [65-67]. CCR7 is a
CKR expressed on a large number of naïve and memory
T cells [47] and therefore does not represent suitable
target. Expression of CCR5, CCR6 and CXCR3 is related
to Th1 (CXCR3 and CCR5) [48,49] or Th17 (CCR6)
cells [68]. Thus, it is possible that CKR agonists, rather
than antagonists, might inhibit Th2 cells in asthma.
Importantly, the chemokine system is highly redundant
with promiscuous chemokine-CKR interactions, suggest-
ing that a single chemokine or CKR could have com-
pensatory mechanisms leading to unexpected side
effects. Moreover, blocking of a single chemokine or
Table 1 Antigen presenting cell targets
Cell type Target Intervention example Mechanism of action and effects Comments
Dendritic
cell
Peroxisome
proliferator-
activated
receptor
gamma
Rosiglitazone and ciglitazone Decrease CCR7 expression on DCs and
diminishes migration [144,145]
-
Sphingosine 1-
phosphate
inhibitor
FTY720 Sequesters lymphocytes in secondary
lymphoid organs; inhibits T cell
migration to the draining lymph nodes
[146-;] suppresses eosinophilic airway
inflammation and AHR, reduced Th2 cell
generation [147,148], generalised
immunosuppression [149]
In clinical study for moderate asthma
(ClinicalTrials.gov identifier:
NCT00785083)
Thymic stromal
lymphopoietin
(TSLP)
Anti-TSLP antibodies [39] TSLP skews DCs to express high levels of
OX40 ligand, which promotes the
generation of Th2 cells [38]; its inhibition
prevents Th2-mediated airway
inflammation in mice [39]
-
CCL2 CCR2 antagonists [150] Overexpressed in lung and increased DC
recruitment in allergic asthma [151,152]
CCR2 is involved in migration of other
immune cells as well
CD80/86
costimulation
D prostanoid 1 receptor
agonist [153], aerosolised CD86
antisense oligonucleotide [154]
or suplatast tosilate [155],
Reduce allergic disease in mice models
of acute asthma
CD80/86 co-stimulation does not
contribute to recall responses of effector
Th2 cells [156] and might not be useful
for the treatment of established disease
OX40L Anti-OX40L Ab Blocks Th2 cell infiltration, cytokine
secretion, IgE production and Th2
inflammation in mouse and non-human
primate models [157]
-
Programmed
death-1 (PD-1)
and PD1
ligands
None so far PD-1 and its ligands regulate T cell
activation and differentiation and affect
asthmatic responses [158]
-
Macrophage Anti-A1
adenosine
receptors
A1 adenosine receptor
modulators
Anti-inflammatory [159] Gene expression and function depends
on polarisation (classical vs. alternative
activation) [160]
Unknown Water-soluble chitosan Suppresses allergic asthma in mice [161]
Unknown Mycolic acid Modulates airway macrophage function
to suppress allergic inflammation in mice
[162]
Basophil Specific target
unknown so
far
N/A CD49b
+FcεR
+ basophils migrate from
blood to lymph nodes, where they
present processed antigen to T cells in
the context of MHC class II molecules
and induce Th2 type polarisation
through secretion of IL-4 [163-166]
Recently, the role of basophils in Th2
immunity was disputed in favour of
inflammatory DCs [167,168]
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redundancy.
CRTH2 is a mediator involved in the migration and
activation of basophils, eosinophils and Th2 cells
[69,70]. CRTH2 inhibition leads to attenuated airway
hyperreactivity and inflammation in animal models [71].
Ramatroban, a dual thrombroxane A2 receptor (TP) and
CRTH2 receptor antagonist, suppresses eosinophil che-
motaxis in vitro and in vivo a n di sa p p r o v e df o rt h e
treatment of allergic rhinitis in Japan [72]. Numerous
other CRTH2 antagonists, such as 4-aminotetrahyrochi-
noline derivatives or indoleacetic acid derivatives, are
currently under development [69,70,72] and OC000459
is in clinical trials for the treatment of allergic asthma
(ClinicalTrials.gov identifier: NCT01057927, NCT00
890877). The CRTH2 receptor is a DP2 receptor. Biolo-
gical effects of PGD2 and PGH2 are mediated by D
prostanoid receptor 1 (DP1) and CRTH2 (DP2). PGD2
activates DP1, thereby affecting NK cells and their cyto-
kine production into a profile more favourable for Th2
skewing [73]. PGH2 is implicated in the accumulation
of CRTH2+ cells at sites of inflammation [74]. Addition-
ally, as discussed above, PGE2 polarises DCs to promote
Th2 cell differentiation and recruitment [34,36,37].
These effects of PGE2 seem to be mediated by PGE2
receptor type 2 (EP2) and type 4 (EP4) [75]. Therefore,
PGs and CRTH2 appear to be promising Th2 cell-speci-
fic targets.
While homing receptors are important for Th2 cell
migration, several adhesion molecules also play a role.
For example, intercellular adhesion molecule (ICAM)-1
and ICAM-2 play important roles in T cell migration in
the lungs [76] and ICAM-1 deficiency reduces leukocyte
infiltration into the airways, as well as IL-4 and IL-5
concentration in bronchoalveolar lavage fluid [77]. Addi-
tionally, VCAM-1 plays a role in eosinophil migration
and activation in addition to T cell trafficking [78].
There are no clinical data to date for mAbs against
ICAM-1 or VCAM-1 in the treatment of asthma. Other
potential adhesion targets include VLA-4 (a4ß1
Table 2 Strategies to inhibit Th2 cell differentiation
Target Mechanism Intervention example Effect Comment
GATA-3 Development of Th2 cells
[169]
Local treatment with GATA-3 antisense
oligonucleotides [170] or RNA
interference delivered by a lentiviral
vector [171]
Inhibits allergen-induced asthma Important for T cell
development, its
inhibition could cause
immunosuppression [169]
STAT3 Important for
differentiation of Th2 cells
[172]
Selective small molecule inhibitors [173] Inhibits allergen-induced asthma -
STAT5a Important for
differentiation of Th2 cells
None known STAT-5a deficient mice have
decreased IL-5 production and Th2
and eosinophil recruitment in mouse
model of asthma [174]
Also important for
development of inducible
Tregs [175]
STAT6 Important for
differentiation of Th2 cells
Selective small molecule inhibitors [176]
or RNA interference [177] of STAT6
Suppresses Th2 responses in vitro and
in animal models
-
Notch Binds to the promoter of
GATA-3 and regulates its
transcription [178,179]
Gamma-secretase inhibitor (GSI) [180] Selective inhibition of Th2, but not
Th1 responses [181]
Involved in development
of many other leukocytes
and organs [182,183]
c-Maf Transcription factor
expressed at high levels in
Th2 cells [184,185]
So-Cheong-Ryong-Tang (a Korean
traditional medicine; [186]) or KR62890
(agonist of peroxisome proliferator-
activated receptor g; [187])
Inhibits Th2 cell functions Inhibits Th-17 and Treg
function
Gfi-1,
Dec2,
ROG and
Bcl-6
Transcription repressors
important for Th2 cell
development [188-192]
None known N/A -
SOCS-3 Inhibitor of cytokine
signalling pathways [193]
None known SOCS-3 blocks Th1 cell development
and is preferentially expressed in Th2
cells [194]
Appears to be involved in
Treg and/or Th17 cell
development [195]
SOCS-5 Inhibitor of cytokine
signalling pathways [193]
None known Preferentially expressed in Th1 cells
and prevents Th2 cell development
[196]
Its over-expression in T
cells enhances airway
inflammation and AHR
[197]
miRNA-
16,
miRNA-
21,
miRNA-
126
Up-regulated in lung
tissue after allergen
challenge in mouse
models of asthma
[198,199]
Anti-miRNA-126 antagomir (small
synthetic RNA molecule with modified
backbone for degradation prevention)
[199]
Prevents allergen-induced airway
hyperreactivity and reduces allergic
inflammation
-
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blocks both a4ß1 and a4ß7 integrins, but was discon-
tinued due to severe side -effects [81]. Novel a4 integrin
mAb LLP2A reduces AHR and inflammation in mouse
allergic asthma [82]. Unfortunately, initial results with
VLA-4 antagonist GW559090 were disappointing [83],
but newer and safer alternative VLA-4 antagonists are
in development [84-86]. Lastly, a pan-selectin inhibitor
is currently in phase IIa clinical trials for COPD, might
also be promising for asthma [81]. None of these adhe-
sion molecules is selectively expressed on Th2 cells.
The anticoagulant heparin has anti-inflammatory
properties that inhibit leukocyte extravasation [87]. IVX-
0142 is a heparin-derived hypersulfated disaccharide
that appears to be well-tolerated and shows a trend
towards attenuation of asthmatic responses, but does
not affect AHR [88]. Additional studies are needed to
evaluate effects of these molecules on Th2 cells.
Inhibition of long-lived Th2 memory cells
It is possible that long-lived Th2 memory cells establish
anti-apoptotic mechanisms for long-term maintenance,
which when inhibited may result in cell death. Interfer-
ing with mechanisms for their longevity in the lungs
may eliminate Th2 cells. Corticosteroids [89], calci-
neurin inhibitors [90] and the cysteine leukotriene
receptor antagonist montelukast [89] have pro-apoptotic
effects on activated T cells, one of the many mechan-
isms that lead to their effectiveness in asthma. CX3CR1
seems to provide a survival signal for lung Th2 and Th1
cells, which when inhibited reduces allergic inflamma-
tion [67]. T cells from p53-deficient mice have
decreased apoptosis and increased Th2 differentiation
[91], cytoxic lymphocyte antigen-4 (CTLA-4) promotes
T cell apoptosis [92,93] and CTLA-4-deficient Th cells
are directed towards Th2 differentiation [94]. Addition-
ally, the ratio of anti-apoptotic protein Bcl-2 over pro-
apoptotic protein Bax in peripheral blood lymphocytes
of asthmatic patients is increased in comparison to
healthy controls [95]. Interestingly, Th2 cells express
less Fas ligand (FasL) and are more resistant to apopto-
sis than other Th subtypes [96,97]. Moreover, the Th2
cytokine IL-4 reduces FasL, while Th1 cytokines IFNg,
TGFb and IL-2 increase FasL expression [89]. Regula-
tion of FasL plays an important role because FasL-
expressing T cells are pivotal during the resolution of
airway inflammation [98] and intratracheal delivery of
DCs co-transfected with FasL and allergen genes before
Table 3 Interference with Th2 signal transduction pathway and their inhibitors
Class Examples of
inhibitor(s)
Effect Reference*
EGF receptor inhibitor Gefitinib Reduces the cell counts and Th2 cytokine levels in an OVA-
challenged mouse model of allergic asthma
[200]
Syk inhibitors BAY 61-3606 Inhibits disease signs in a mouse model of asthma [201]
R112 Reduces allergic rhinitis upon intranasal administration [202]
JAK3 inhibitors CP690550 Blocks expression and signalling of IL-2, IL-4 and IL-13 [203]
WHI-P131 and WHI-
P97
Interferes with inflammatory mediators and mast cell
degranulation in animal models of asthma
[204,205]
p38 MAPK/ERK inhibitor U0126 Inhibits airway and lung inflammation in mouses model of
asthma
Role of p38 in steroid resistant asthma patients is investigated
in a clinical trial
[206]
NCT00676572
Inhaled p38 MAPK antisense oligonucleotide ISIS101757 Inhibits allergic immunity in mice [207]
p38a inhibitors BIRB796, SB203580
and RWJ67657
Inhibits airway and lung inflammation in mouse models of
asthma
[208-210]
JNK inhibitor SP600125 Inhibits T cell cytokine production and lung inflammation in
mouse models of asthma
[211,212]
Inhibitor of adenosine A1, A2b and A3
receptors, p38 MAPK and PDE4D
CGH2466 Inhibits allergic asthma in mice [213]
PI3K inhibitors Wortmannin and
Ly294002
Inhibits allergic asthma in mice [214,215]
Inhibitor of IkappaB kinase-2 (IKK-2) N/A Reduces allergen-induced airway inflammation and AHR in
animal models of asthma
[216,217]
IkappaB ubiquitination inhibitor GS143 Represses Th2, but not Th1 differentiation after allergen
challenge in a mouse model of allergic asthma
[218]
Selective PDE4 inhibitors GSK256066, MK-0359 Inhibits the fall in lung function in patients with asthma caused
by inhaled allergen challenge
[219,220]
PDE3 and PDE4 inhibitors RPL554 Inhibits eosinophil recruitment following antigen challenge in
guinea pigs
[221]
* Numbers starting with NTC represent clinical study code from http://clinicaltrials.gov/
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Cytokine Relation to Th2 cells in asthma References Was the target used in clinical trials in asthma? Clinical study,
Reference*
IL-2 Important for survival of mature Tregs
Required for generation of effector and
survival of memory T cells
[175]
[222]
Yes, daclizumab targeting its soluble IL-2 receptor CD25,
improves FEV1 and reduced daily asthma symptoms
NCT00028288
IL-3 Secreted by Th2 cells, regulates eosinophil
and basophil differentiation, migration
and survival
Inhibition of IL-3/IL-5/GM-CSF common b
receptor inhibits Th2 differentiation
[223,224]
[225]
No -
IL-4 Crucial for Th2 cell differentiation
Induction of IgE production of B cells
[226] Yes, numerous mAbs and other compounds, development
of most mAbs was discontinued, pitrakinra (IL-4 mutant
protein binding to IL-4 and IL-13 receptors) improves lung
function, stabilises asthma symptom scores and reduces
beta-agonist use
[9,11,227-229],
NCT00801853,
NCT00941577
IL-5 Th2 cell cytokine involved in eosinophil
differentiation, maturation, recruitment
and survival
[230,231] Yes, does not inhibit eosinophilia or AHR, but new
indications suggest use in difficult-to-treat and severe
asthma
[232-234],
NCT01000506,
NCT00292877
IL-6 Polarises CD4+ T cells to Th2 or Th17
subtype
Soluble IL-6 receptor induces apoptosis of
Th2 cells in the lungs & induces Tregs
[235,236]
[237]
No -
IL-9 Secreted by Th2 cells
Over expression in mice enhances
inflammation and AHR
[238]
[239,240]
Yes, appears to have acceptable safety profile and to
decrease FEV1
[241,242]
IL-10 Secreted by Th2 cells and some Tregs,
plays multiple roles in the immune
processes
[243] No -
IL-12 Essential for differentiation, proliferation
and activation of Th1 cells
Suppresses Th2 immune responses in
murine models
[244]
[245]
Yes, reduction in the number of circulating blood
eosinophils, but not sputum eosinophilia, the late-phase
response or airway hyper-responsiveness
[246]
IL-13 Involved in lung inflammation, mucus
hypersectretion, subepithelial fibrosis and
eotaxin production
[247] Yes, clinical trials for numerous mAbs are in progress;
pitrakinra (IL-4 mutant protein binding to IL-4 and IL-13
receptors) improves lung function, stabilises asthma
symptom scores and reduces beta-agonist use
[229,248,249],
(NCT00873860,
NCT00801853,
NCT00941577)
IL-15 Th1 cytokine that appears to
counterbalance Th2 immune response
[250] No -
IL-17A Implicated in infiltration of neutrophils
after allergen exposure
Might regulate established Th2 response
[251]
[252]
No -
IL-17F Implicated in infiltration of neutrophils
after allergen exposure
[251] No -
IL-18 Cytokine involved in Th1 and Th2
immunity
Delivery of IL-18 gene reduced allergic
inflammation in a mouse asthma model
[253]
[254]
No -
IL-19 Produced by epithelial cells and mediates
IL-4, IL-5, IL-10 and IL-13 production
[255,256] No -
IL-21 Secreted by CD4+ T cells
Involved in proliferation, differentiation
and regulation of T cells, B cells, DCs and
natural killer cells
Stimulates IgG responses instead of IgE
[23,257] No -
IL-22 Required for the onset of allergic asthma
in mice, but negatively regulates acute
inflammation in lungs
[258] No -
IL-23 Lung-specific expression enhances
allergen-induced inflammation, mucus
hyperproduction and AHR
Its inhibition protects against allergic
asthma in mice
[259]
[260]
No -
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Page 7 of 17allergen challenge-induced T cell apoptosis and
decreased airway inflammation in mice [99]. Induction
of Fas expression on Th2 cells might be a possible treat-
ment approach that would decrease their survival in the
lungs despite the fact that Th2 cells are somewhat resis-
tant to Fas-induced apoptosis. An additional important
pathway for apoptosis in T cells involves granzyme B,
which is critical for activation-induced cell death [100].
Inhibition of granzyme B rescues Th2 cells from apopto-
sis [100], suggesting that selective activation of gran-
zyme B in Th2 cells might be a novel target. Another
possibility is that increased apoptosis of Tregs and their
protection from apoptosis might be a method of treating
disease but there is little information related to cell
death of Tregs in allergic diseases and it is possible that
dysregulated apoptosis of Tregs may contribute to aller-
gic asthma [90].
New categories of targets: Statins and Rho kinases; TIM
proteins; Galectins; Siglecs; Arginases; Histone
deacetylase inhibitors; Pathogens and Toll-like receptors
Statins are a class of cholesterol lowering drugs that also
possess anti-inflammatory and immune properties
[101,102]. Simvastatin, Lovastatin and Pravastatin
reduced eosinophilia and Th2 cytokines in animal mod-
els of asthma [103-105]. Clinical trials evaluating Sim-
vastatin (NCT00792337), Lovastatin (NCT00689806)
and Atorvastatin (NCT00463827), are ongoing or com-
pleted, but data are not yet available. Some statins exert
their action through regulation of Rho kinases [106],
which are expressed at high levels in airway smooth
muscle and regulate their contractility [107], but inhibi-
tion appears to impair lymphocyte cytokine secretion
[108].
The genes for the T cell immunoglobulin domain and
mucin domain (TIM) proteins are encoded in the T cell
and airway phenotype regulator region on chromosome
11 [109]. Initial results indicate that although TIM-1 is
involved in Th2 cell differentiation and is associated
with Th2-mediated diseases [110], it also regulates Th17
and Treg development. Furthermore, TIM proteins are
expressed by other immune- cell types [111]. Because
TIM proteins do not exclusively regulate Th2 cells, they
are less useful as targets than originally anticipated.
Galectins are b-galactoside-binding proteins that bind
to glycan residues on the surface of mammalian cells
[112]. Examples are Galectin-3 and -9, which appear to
have numerous functions in T cell activation, differen-
tiation and apoptosis [112]. Airway inflammation and
challenge is decreased in Galectin-3 knockout mice
[113] and intranasal administration of a plasmid encod-
ing Galectin-3 abates chronic airway inflammation in a
murine model of asthma [114]. Galectin-9 binds to
TIM-3, which is expressed on Th1 cells and is impor-
tant for protective immunity against microbes [111] and
intravenous administration of Galectin-9 suppresses
AHR and airway inflammation in a mouse model of
asthma [115].
Siglecs are sialic acid-recognising Ig-superfamily lec-
tins [116]. CD33-related Siglecs, which in humans
Table 4 Effector cytokines as targets (Continued)
IL-25 Induces Th2 immunity, enhances Th2 cell
survival and stimulates Th2 cytokine
secretion
Its inhibition prevents inflammation in
mouse models of asthma
[261,262] No -
IL-27 Th1 cytokine decreases Th2 response in
murine models of asthma
[263] No -
IL-31 Secreted by Th2 cells, expressed at higher
levels in asthmatic patients
[264,265] No -
IL-33 IL-33 receptor, ST2, is a marker for Th2
cells
IL-33 activates Th2 cells
[266,267]
[268]
No -
IFN-g Th1 cytokine that inhibits Th2 cell
polarisation in vitro
Appears to be involved in pathogenesis
of severe allergic asthma
[40]
[269,270]
Yes, but treatment did not improve monitored clinical
parameters
[271]
TGF-ß TGF-ß inhibits expression of transcription
factor GATA-3
Its neutralisation exacerbates or has no
effect on inflammatory responses in
mouse models of asthma
[272]
[273,274]
No -
TNF-a Pleiotropic cytokine, chemoattractant for
eosinophils and contributes to the
activation of T cells
[275] Yes, divergent results, severe side-effects [276,277]
* Numbers starting with NTC represent clinical study code from http://clinicaltrials.gov/
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nantly found on human leukocytes and involved in
innate immunity [116,117]. Mouse Siglec-F, the equiva-
lent of human Siglec-8, is expressed on eosinophils and
regulates their apoptosis [118]. Blocking Siglec-F func-
tion with a mAb reduces airway and lung eosinophilia
in mice [119]. Although Siglec-8 is a promising target
directed against eosinophils, human T lymphocytes
express little or no siglec molecules [120] and do not
appear to be a candidate for inhibiting Th2 cells.
Arginase I and II are cationic amino acid transporters
involved in the metabolism of basic amino acids
expressed in inflammatory lesions of patients with aller-
gic asthma [121-123]. Arginase gene expression and
enzyme activity are enhanced by IL-4 and IL-13
[122,123]. Inhibition of arginase I by RNA interference
suppresses IL-13-mediated AHR in a murine model of
asthma [124] and inhalation of an arginase inhibitor
decreases AHR and airway inflammation in a guinea pig
model of asthma [122]. Conversely, deletion of arginase
in macrophages impairs their ability to suppress Th2-
dependent inflammation and fibrosis [125]. Further
research is needed in order to clarify the role of argi-
nases in Th2 immunity.
Histone deacetylases (HDAC) appear to play an
important role in cytokine transcription [126]. Corticos-
teroid signalling requires HDAC2 to suppress inflamma-
tory gene products and HDAC2 activity is diminished in
corticosteroid-resistance [9]. HDAC inhibitor Trichosta-
tin A reduces allergic airway inflammation by decreasing
expression of the Th2 cytokines, IL-4, IL-5 and IgE
[127]. In contrast, HDAC1 appears to be a negative reg-
ulator of Th2 cytokine expression [128]. Chromatin
modification enzymes might be potential targets for
inhibition of Th2-mediated diseases.
Many microbials or their proteins inhibit Th2 immune
responses in murine models of asthma by polarising
towards Th1 immunity [129-131] or by generating sup-
pressive Tregs [132,133]. Interestingly, microbial agents
have both time- and dose-dependent effects on allergic
asthma [134,135]. Certain allergens such as dust mite
Der p2 and Der f2, bind LPS and are related to the
MD-2 protein of the LPS-binding component of the
TLR4 signalling complex [136,137], which might influ-
ence the induction of Th2 responses demonstrating a
potential for microbials augmenting rather than redu-
cing Th2 responses. Alternatively, bacterial DNA or che-
mically synthesised de novo unmethylated CpG are
immunostimulatory ligands that bind to TLR9 and
induce strong Th1 immune responses [reviewed in
[138]]. Such bacterial and synthetic DNA immunostimu-
latory oligonucleotides (ISS-ODNs) containing CpG
motifs suppress Th2 responses during the sensitisation
phase or immediately before challenge in experimental
asthma [reviewed in [139]]. They have therapeutic and
prophylactic properties [140], including suppression of
DC migration and co-stimulatory molecule expression
and inhibition of IgE-dependent Th2 cytokine release
from mast cells and basophils [141,142]. Moreover, ISS-
ODNs added to allergen immunotherapy significantly
reduce clinical symptoms in patients with asthma [143].
Conclusions
Th2 cells and/or their secreted effector molecules med-
iate the immune response to allergens and are triggered
by exposure to specific allergens leading to allergic
asthma. Thus, inhibiting or eliminating Th2 cells is a
beneficial strategy for treating asthma as long as gener-
alised immunosuppression is avoided. Additionally, it is
especially important to consider targeting Th2 cells
early in disease because when disease is chronic addi-
tional factors may cause perpetuation. Although there
are a myriad of potential Th2 targets (Figure 2), the
Figure 2 Promising cellular and molecular target candidates
for inhibiting memory Th2 cells in allergic asthma are grouped
according to the subchapters of the text. Targets in the inner
circle (dash line) were tested in clinical trials, whereas other targets
are still in pre-clinical stages. Treatment targets are divided into the
following categories: Red colour indicates target inhibition; Blue
colour indicates target activation; and Green colour indicates targets
that can be inhibited or activated to inhibit Th2 cells. For details,
please refer to the text. Abbreviations: DC - dendritic cell; FasL - Fas
ligand; IL - interleukin; IL-25R - interleukin 25 receptor; IL-33R -
interleukin 33 receptor; miRNA - microRNA; M - macrophage; PDE
- phosphodiesterase; STAT - Signal transducer and activator of
transcription; Th1 - helper T cell type 1; Th2 - helper T cell type 2;
TLR - Toll like receptor; Treg - regulatory T cell; TSLP - thymic
stromal lymphopoietin.
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remains elusive.
Aside from anti-IgE therapy for severe asthma, there
are no major new drugs for the treatment of asthma in
the last 20 years. The latest research in allergic asthma
that has elucidated key factors governing Th2 immunity
and identified potential targets is predominantly from
animal models. Now, the challenge is to discover candi-
dates, which best translate from animal models to
patients. However, choosing the most effective new drug
target candidate is especially difficult because human
data is often lacking or incomplete. Additionally, the use
of accurate, predictive biomarkers to evaluate Th2-mod-
ulating drugs such as FEV1, Quality of Life, reduction in
steroid use, decrease allergen-induced late phase
response and others are important to ensure that the
efficacy/adverse effect profiles are standardised and
enable easier decision-making for the best candidates.
We would argue that the most promising new com-
pounds for the clinic are those in which proof of con-
cept in patients is established e.g. anti-IL-13 antibodies
and CRTH2 antagonists. Other candidates currently
tested in the clinic are anti-IL-5, anti-IL-4 and anti-IL-9
compounds and CCR4 antagonists. However, based on
available human data, we suggest that the epithelial cell-
derived cytokines TSLP, IL-25 and IL-33, which drive
Th2 responses are the most promising candidates, with
TLSP the clear frontrunner.
Steroids are efficient for treating asthma because they
inhibit numerous pro-inflammatory responses and
induce numerous anti-inflammatory pathways. Thus,
targeting a single mediator may not suffice for the treat-
ment of allergic asthma because of the redundant
immune and inflammatory pathways involved upon
allergen challenge. Thus, we suggest that targeting more
than one molecule simultaneously using dual specific
antibody/protein platforms to engineer new drugs will
be the next major approach in drug discovery. However,
while this approach creates a scenario in which numer-
ous targets can be combined, the caveat is that optimal
candidates must be carefully chosen. Another important
consideration for the therapeutic strategy for allergic
asthma is that drugs may need to be developed for spe-
cific subtypes of disease in which particular cellular and
molecular pathways drive the disease. One example is
the anti-IL-5 mAb, which is only effective in asthmatics
with very high sputum and lung eosinophil numbers.
This example suggests that it is beneficial to better cate-
gorise patients and consider personalised medicine
based on a clear classification of disease.
These are exciting times for Th2 cell immunology as
the results of basic research are defining key molecu-
lar and cellular components in the response to aller-
gens. This information is already being converted to
targets that are being tested in the clinic. Currently,
irrespective of approach, we consider that a successful
strategy for the treatment of allergic asthma will
include a selective inhibition of Th2 cells with the
ultimate aim of eliminating allergen-specific Th2
immune responses. We anticipate that new candidates
will be approved in the near future and offer treat-
ment options for patients suffering with asthma and
other allergic diseases.
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